MEP0808A - Karbonilamino pirolopirayoli, snažni inhibitori kinaza - Google Patents

Karbonilamino pirolopirayoli, snažni inhibitori kinaza

Info

Publication number
MEP0808A
MEP0808A MEP-08/08A MEP808A MEP0808A ME P0808 A MEP0808 A ME P0808A ME P808 A MEP808 A ME P808A ME P0808 A MEP0808 A ME P0808A
Authority
ME
Montenegro
Prior art keywords
carbonylamino
kinase inhibitors
pyrrolopyrazoles
potent kinase
compounds
Prior art date
Application number
MEP-08/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Liming Dong
Chuangxing Guo
Yufeng Hong
Mary Catherine Johnson
Susan Elizabeth Kephart
Haitao Li
Indrawan James Mcalpine
Jayashree Girish Tikhe
Anle Yang
Junhu Zhang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ME00006B publication Critical patent/ME00006B/me
Publication of MEP0808A publication Critical patent/MEP0808A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MEP-08/08A 2005-12-21 2006-12-12 Karbonilamino pirolopirayoli, snažni inhibitori kinaza MEP0808A (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75334905P 2005-12-21 2005-12-21
US86493206P 2006-11-08 2006-11-08
PCT/IB2006/003646 WO2007072153A2 (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

Publications (2)

Publication Number Publication Date
ME00006B ME00006B (me) 2010-02-10
MEP0808A true MEP0808A (xx) 2010-02-10

Family

ID=38189022

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-08/08A MEP0808A (xx) 2005-12-21 2006-12-12 Karbonilamino pirolopirayoli, snažni inhibitori kinaza

Country Status (27)

Country Link
US (1) US7884117B2 (xx)
EP (1) EP1979356B1 (xx)
JP (1) JP4635089B2 (xx)
KR (1) KR101029167B1 (xx)
AP (1) AP2369A (xx)
AU (1) AU2006327866B2 (xx)
BR (1) BRPI0620354A2 (xx)
CA (1) CA2634381C (xx)
CR (1) CR10094A (xx)
CU (1) CU23751B7 (xx)
DK (1) DK1979356T3 (xx)
EA (1) EA015513B1 (xx)
EC (1) ECSP088558A (xx)
ES (1) ES2435405T3 (xx)
GE (1) GEP20104974B (xx)
HK (1) HK1128290A1 (xx)
HR (1) HRP20130976T1 (xx)
IL (1) IL191776A (xx)
MA (1) MA30076B1 (xx)
ME (1) MEP0808A (xx)
MY (1) MY151455A (xx)
NO (1) NO20082482L (xx)
NZ (1) NZ568692A (xx)
PL (1) PL1979356T3 (xx)
PT (1) PT1979356E (xx)
RS (2) RS53029B (xx)
WO (1) WO2007072153A2 (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
CN102596204B (zh) 2009-07-06 2016-11-23 波涛生命科学有限公司 新的核酸前药及其使用方法
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2012039448A1 (ja) * 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
CN103298461A (zh) 2010-11-17 2013-09-11 霍夫曼-拉罗奇有限公司 治疗肿瘤的方法
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
ES2626488T3 (es) 2011-07-19 2017-07-25 Wave Life Sciences Pte. Ltd. Procedimientos para la síntesis de ácidos nucleicos funcionalizados
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
JP2015511598A (ja) 2012-03-16 2015-04-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐａｋ１阻害剤を用いて黒色腫を治療する方法
SG11201500232UA (en) 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
EP2873674B1 (en) 2012-07-13 2020-05-06 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
CN106068325B (zh) 2014-01-16 2021-07-09 波涛生命科学有限公司 手性设计
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JP6690543B2 (ja) 2014-10-31 2020-04-28 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物
JP6854762B2 (ja) * 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
JP6787314B2 (ja) * 2015-06-15 2020-11-18 宇部興産株式会社 置換ジヒドロピロロピラゾール誘導体
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
EP3885347B1 (en) 2018-11-14 2023-11-22 UBE Corporation Dihydropyrrolopyrazole derivative
JP2022517740A (ja) * 2018-12-28 2022-03-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
EP3956446A1 (en) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1320531E (pt) * 2000-08-10 2010-10-27 Pfizer Italia Srl Biciclo-pirazoles activos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas compreendendo estes
WO2004013144A1 (en) 2002-07-25 2004-02-12 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0229526D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
CA2539549A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
SI1838718T1 (sl) * 2005-01-10 2011-08-31 Pfizer Pirolopirazoli, zmogljivi inhibitorji kinaze

Also Published As

Publication number Publication date
WO2007072153A3 (en) 2007-10-25
US7884117B2 (en) 2011-02-08
ME00006B (me) 2010-02-10
IL191776A (en) 2013-03-24
WO2007072153A8 (en) 2008-08-14
NO20082482L (no) 2008-07-02
IL191776A0 (en) 2008-12-29
KR20080080567A (ko) 2008-09-04
WO2007072153A2 (en) 2007-06-28
NZ568692A (en) 2011-07-29
DK1979356T3 (da) 2013-11-18
JP4635089B2 (ja) 2011-02-16
CR10094A (es) 2008-08-01
EP1979356A2 (en) 2008-10-15
MA30076B1 (fr) 2008-12-01
HK1128290A1 (en) 2009-10-23
CA2634381A1 (en) 2007-06-28
BRPI0620354A2 (pt) 2011-11-08
PL1979356T3 (pl) 2014-01-31
CA2634381C (en) 2011-03-08
GEP20104974B (en) 2010-04-26
ES2435405T3 (es) 2013-12-19
MY151455A (en) 2014-05-30
CU20080115A7 (es) 2010-08-30
AP2008004506A0 (en) 2008-06-30
KR101029167B1 (ko) 2011-04-12
RS20080281A (xx) 2009-09-08
CU23751B7 (es) 2012-01-31
RS53029B (en) 2014-04-30
ECSP088558A (es) 2008-07-30
AU2006327866A1 (en) 2007-06-28
PT1979356E (pt) 2013-11-21
HRP20130976T1 (hr) 2013-11-22
EA200801291A1 (ru) 2008-12-30
AU2006327866B2 (en) 2012-06-14
US20090318440A1 (en) 2009-12-24
AP2369A (en) 2012-02-29
EA015513B1 (ru) 2011-08-30
JP2009520805A (ja) 2009-05-28
EP1979356B1 (en) 2013-09-18

Similar Documents

Publication Publication Date Title
MY151455A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
MX2008001538A (es) Aril piridinas y metodos para su uso.
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
MXPA05012026A (es) Compuestos de azaindol como inhibidores de cinasa.
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
WO2007079164A3 (en) Protein kinase inhibitors
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
MY148634A (en) Pyridazinone derivatives
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
EA200800357A1 (ru) Новые фармацевтические соединения
GB0400895D0 (en) Chemical compounds
UA87494C2 (xx) Азаіндоли як інгібітори кіназ януса (jak) та інших протеїнкіназ[азаиндолы как ингибиторы киназ януса (jak) и других протеинкиназ
TW200628153A (en) Novel compounds
TW200624429A (en) Novel cysteine protease inhibitors
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
WO2006097809A3 (en) Novel tyrosine derivatives
UA92047C2 (xx) Карбоніламінопіролпіразоли - потужні інгібітори кінази[карбониламинопирролпиразолы - мощные ингибиторы киназы
DE602006016430D1 (de) Phosphodiesteraseinhibitoren auf azolbasis
UA88794C2 (xx) Піролопіразоли як сильнодіючі інгібітори кінази[пирролопиразолы как сильнодействующие ингибиторы киназы
MXPA05011594A (es) Intermediarios de imidazopiridina.
CY1114511T1 (el) Καρβονυλαμινο πυρρολοπυραζολες, ικανοι αναστολεις κινασων